
|Peer-Reviewed|December 23, 2020
Supplemental Material: Clinical and Economic Burden of Intravenous Paclitaxel or nab-Paclitaxel for Metastatic Breast Cancer
Supplemental materials for the article describing treatment patterns, toxicities, and health care service utilization and costs of women with metastatic breast cancer (mBC) initiating treatment with intravenous (IV) paclitaxel or IV nab-paclitaxel.
Advertisement
Articles in this issue
over 4 years ago
ASH 2020: Clinical Updatesover 4 years ago
ASH 2020: COVID-19 and Hematologyover 4 years ago
ASH 2020: CAR T-Cell Therapy Updatesover 4 years ago
ASH 2020: The Next Waveover 4 years ago
2020 SABCS: Topics in Precision OncologyNewsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Leucovorin Treatment Expansion for Autism Symptoms Under FDA Review
2
US, Japan Patients With Diabetes Discontinue Semaglutide After First Year
3
How Clinician-Led Partnerships Strengthen Post-Acute Care
4
Contributor: Medication Adherence as a Journey—A Year-Round Strategy for Medicare Advantage Success
5